Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch BioPharma DiveA strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive A strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growthNext: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy Related Stories Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026
